Diabetes medications with cardiovascular protection in the wake of EXSCEL: is there a class effect for long-acting GLP-1 receptor agonists?
暂无分享,去创建一个
[1] G. Dagenais,et al. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide , 2018, Diabetes, obesity & metabolism.
[2] Neha J. Pagidipati,et al. Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes , 2017, The New England journal of medicine.
[3] R. DeFronzo,et al. What now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement each other to save lives? , 2017 .
[4] J. Buse,et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.
[5] Lawrence A Leiter,et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.
[6] R. DeFronzo,et al. Diabetes medications with cardiovascular protection – what now after LEADER®? Could metformin, pioglitazone, empagliflozin and liraglutide complement each other to save lives? , 2016 .
[7] S. Solomon,et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. , 2015, The New England journal of medicine.
[8] R. DeFronzo,et al. Diabetes medications with cardiovascular protection in the wake of EMPA-REG OUTCOME: The optimal combination may be metformin, pioglitazone and empagliflozin , 2015 .
[9] R. Ryder. The potential risks of pancreatitis and pancreatic cancer with GLP‐1‐based therapies are far outweighed by the proven and potential (cardiovascular) benefits , 2013, Diabetic medicine : a journal of the British Diabetic Association.